Lamisil (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, preventing the synthesis of ergosterol, a vital component of fungal cell membranes. This disruption leads to accumulation of toxic squalene and ultimately kills the fungal cells.

The specific dosage and frequency of Lamisil are determined by the prescribing healthcare professional based on the infection type, severity, patient age, and treatment guidelines. Patients should follow the prescriber's instructions precisely.

Safety data for topical terbinafine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lamisil (terbinafine) belongs to the allylamine class, which often provides rapid fungicidal activity and shorter treatment courses compared with azole antifungals. Its topical formulation is convenient for localized skin infections, while systemic options may be preferred for extensive disease.

Lamisil should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain its stability and effectiveness.

Apply a thin layer of the cream to the affected skin area once or twice daily, as directed by the prescriber. Gently rub in until fully absorbed, and wash hands after application to avoid accidental contact with eyes or mucous membranes.

Serious but rare risks include severe allergic reactions such as Stevens‑Johnson syndrome, systemic hepatic toxicity, and anaphylaxis. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, fever, jaundice, or difficulty breathing.

Lamisil should not be used by individuals with known hypersensitivity to terbinafine or any component of the formulation. It is also contraindicated on broken, inflamed skin or mucous membranes, and should be avoided in patients with severe liver disease without medical supervision.